These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 37575247)

  • 1. Response to SARS-CoV-2 initial series and additional dose vaccine in pediatric patients with predominantly antibody deficiency.
    Tandon M; DiGiacomo DV; Zhou B; Hesterberg P; Rosenberg CE; Barmettler S; Farmer JR
    Front Immunol; 2023; 14():1217718. PubMed ID: 37575247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to Severe Acute Respiratory Syndrome Coronavirus 2 Initial Series and Additional Dose Vaccine in Patients With Predominant Antibody Deficiency.
    Barmettler S; DiGiacomo DV; Yang NJ; Lam T; Naranbhai V; Dighe AS; Burke KE; Blumenthal KG; Ling M; Hesterberg PE; Saff RR; MacLean J; Ofoman O; Berrios C; St Denis KJ; Lam EC; Gregory D; Iafrate AJ; Poznansky M; Lee H; Balazs A; Pillai S; Farmer JR
    J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1622-1634.e4. PubMed ID: 35381395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular immune response to SARS-CoV-2 in patients with primary antibody deficiencies.
    Mizera D; Dziedzic R; Drynda A; Gradzikiewicz A; Jakieła B; Celińska-Löwenhoff M; Padjas A; Matyja-Bednarczyk A; Zaręba L; Bazan-Socha S
    Front Immunol; 2023; 14():1275892. PubMed ID: 37901210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine response in adults with predominantly antibody deficiency.
    Zhang AM; Elmoursi A; DiGiacomo DV; Zhou B; Tandon M; Hong JS; Yang NJ; Ong MS; Dighe AS; Berrios C; Poznansky MC; Iafrate AJ; Naranbhai V; Balazs A; Pillai S; Farmer JR; Barmettler S
    J Allergy Clin Immunol Glob; 2024 May; 3(2):100234. PubMed ID: 38544577
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 Vaccine Induced Atypical Immune Responses in Antibody Defects: Everybody Does their Best.
    Salinas AF; Mortari EP; Terreri S; Quintarelli C; Pulvirenti F; Di Cecca S; Guercio M; Milito C; Bonanni L; Auria S; Romaggioli L; Cusano G; Albano C; Zaffina S; Perno CF; Spadaro G; Locatelli F; Carsetti R; Quinti I
    J Clin Immunol; 2021 Nov; 41(8):1709-1722. PubMed ID: 34669144
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 booster vaccination rescues attenuated IgG1 memory B cell response in primary antibody deficiency patients.
    Lin FJ; Doss AMA; Davis-Adams HG; Adams LJ; Hanson CH; VanBlargan LA; Liang CY; Chen RE; Monroy JM; Wedner HJ; Kulczycki A; Mantia TL; O'Shaughnessy CC; Raju S; Zhao FR; Rizzi E; Rigell CJ; Dy TB; Kau AL; Ren Z; Turner JS; O'Halloran JA; Presti RM; Fremont DH; Kendall PL; Ellebedy AH; Mudd PA; Diamond MS; Zimmerman O; Laidlaw BJ
    Front Immunol; 2022; 13():1033770. PubMed ID: 36618402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defining Clinical and Immunological Predictors of Poor Immune Responses to COVID-19 mRNA Vaccines in Patients with Primary Antibody Deficiency.
    Shin JJ; Par-Young J; Unlu S; McNamara A; Park HJ; Shin MS; Gee RJ; Doyle H; Afinogenova Y; Zidan E; Kwah J; Russo A; Mamula M; Hsu FI; Catanzaro J; Racke M; Bucala R; Wilen C; Kang I
    J Clin Immunol; 2022 Aug; 42(6):1137-1150. PubMed ID: 35713752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hybrid Immunity Shifts the Fc-Effector Quality of SARS-CoV-2 mRNA Vaccine-Induced Immunity.
    Bowman KA; Stein D; Shin S; Ferbas KG; Tobin NH; Mann C; Fischinger S; Ollmann Saphire E; Lauffenburger D; Rimoin AW; Aldrovandi G; Alter G
    mBio; 2022 Oct; 13(5):e0164722. PubMed ID: 36000735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B Cell Response Induced by SARS-CoV-2 Infection Is Boosted by the BNT162b2 Vaccine in Primary Antibody Deficiencies.
    Pulvirenti F; Fernandez Salinas A; Milito C; Terreri S; Piano Mortari E; Quintarelli C; Di Cecca S; Lagnese G; Punziano A; Guercio M; Bonanni L; Auria S; Villani F; Albano C; Locatelli F; Spadaro G; Carsetti R; Quinti I
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 antibody vaccine response in Inflammatory Bowel Disease patients with positive anti-nucleocapsid serology or history of COVID-19 infection.
    Hoyois A; Gulkilik C; Mekkaoui L; Dahma H; Wambacq V; Minsart C; Rosewick N; Liefferinckx C; Amininejad L; Van Gossum A; Cremer A; Vandenberg O; Franchimont D
    Acta Gastroenterol Belg; 2024; 87(2):263-273. PubMed ID: 39210758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 T Cell Response in Severe and Fatal COVID-19 in Primary Antibody Deficiency Patients Without Specific Humoral Immunity.
    Steiner S; Schwarz T; Corman VM; Gebert L; Kleinschmidt MC; Wald A; Gläser S; Kruse JM; Zickler D; Peric A; Meisel C; Meyer T; Staudacher OL; Wittke K; Kedor C; Bauer S; Besher NA; Kalus U; Pruß A; Drosten C; Volk HD; Scheibenbogen C; Hanitsch LG
    Front Immunol; 2022; 13():840126. PubMed ID: 35359967
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.
    Macrae K; Martinez-Cajas J; Bessai K; Abdulhamed A; Gong Y
    Curr Oncol; 2022 Sep; 29(10):7059-7071. PubMed ID: 36290831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects.
    Wheeler SE; Shurin GV; Yost M; Anderson A; Pinto L; Wells A; Shurin MR
    Microbiol Spectr; 2021 Sep; 9(1):e0034121. PubMed ID: 34346750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody levels following vaccination against SARS-CoV-2: associations with post-vaccination infection and risk factors in two UK longitudinal studies.
    Cheetham NJ; Kibble M; Wong A; Silverwood RJ; Knuppel A; Williams DM; Hamilton OKL; Lee PH; Bridger Staatz C; Di Gessa G; Zhu J; Katikireddi SV; Ploubidis GB; Thompson EJ; Bowyer RCE; Zhang X; Abbasian G; Garcia MP; Hart D; Seow J; Graham C; Kouphou N; Acors S; Malim MH; Mitchell RE; Northstone K; Major-Smith D; Matthews S; Breeze T; Crawford M; Molloy L; Kwong ASF; Doores K; Chaturvedi N; Duncan EL; Timpson NJ; Steves CJ
    Elife; 2023 Jan; 12():. PubMed ID: 36692910
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Seroprevalence and Improved Antibody Responses Following Third Primary SARS-CoV-2 Immunisation: An Update From the COV-AD Study.
    Shields AM; Faustini SE; Hill HJ; Al-Taei S; Tanner C; Ashford F; Workman S; Moreira F; Verma N; Wagg H; Heritage G; Campton N; Stamataki Z; Drayson MT; Klenerman P; Thaventhiran JED; Elkhalifa S; Goddard S; Johnston S; Huissoon A; Bethune C; Elcombe S; Lowe DM; Patel SY; Savic S; Richter AG; Burns SO;
    Front Immunol; 2022; 13():912571. PubMed ID: 35720400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and tolerability of COVID-19 messenger RNA vaccines in primary immunodeficiency patients with functional B-cell defects.
    Pham MN; Murugesan K; Banaei N; Pinsky BA; Tang M; Hoyte E; Lewis DB; Gernez Y
    J Allergy Clin Immunol; 2022 Mar; 149(3):907-911.e3. PubMed ID: 34952033
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of efficacy and longevity of immune response to third and fourth doses of COVID-19 vaccines in patients with cancer: A single arm clinical trial.
    Thakkar A; Pradhan K; Duva B; Carreno JM; Sahu S; Thiruthuvanathan V; Campbell S; Gallego S; Bhagat TD; Rivera J; Choudhary G; Olea R; Sabalza M; Shapiro LC; Lee M; Quinn R; Mantzaris I; Chu E; Will B; Pirofski LA; Krammer F; Verma A; Halmos B
    Elife; 2023 Mar; 12():. PubMed ID: 36975207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SARS-CoV-2-Specific and Functional Cytotoxic CD8 Cells in Primary Antibody Deficiency: Natural Infection and Response to Vaccine.
    Gupta S; Agrawal S; Sandoval A; Su H; Tran M; Demirdag Y
    J Clin Immunol; 2022 Jul; 42(5):914-922. PubMed ID: 35366743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
    Kennedy NA; Lin S; Goodhand JR; Chanchlani N; Hamilton B; Bewshea C; Nice R; Chee D; Cummings JF; Fraser A; Irving PM; Kamperidis N; Kok KB; Lamb CA; Macdonald J; Mehta S; Pollok RC; Raine T; Smith PJ; Verma AM; Jochum S; McDonald TJ; Sebastian S; Lees CW; Powell N; Ahmad T;
    Gut; 2021 Oct; 70(10):1884-1893. PubMed ID: 33903149
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.
    Christensen IE; Jyssum I; Tveter AT; Sexton J; Tran TT; Mjaaland S; Kro GB; Kvien TK; Warren DJ; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Grødeland G; Lund-Johansen F; Jørgensen KK; Syversen SW; Goll GL; Provan SA
    BMC Med; 2022 Oct; 20(1):378. PubMed ID: 36199139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.